PRECISIONvalue’s 2021 Care Management Survey found that Oncology was the top condition for which patients were referred for Care Management, and tools, resources and programs for supporting medication adherence were the top type of support that respondents would like to receive from pharmaceutical manufacturers.
Oral chemotherapy agents comprise up 25% to 35% of oncology drugs in development; oral therapies are an increasing component of cancer treatment and anticipated to be a much larger component in ensuing years.
This transition presents challenges for Care Managers and other stakeholders within the healthcare ecosystem, including:
- Varied patient perceptions and preferences
- Delivery system revenue considerations (eg, impact on hospital system revenue streams; preferences by capitated systems for oral therapies to reduce infusion costs)
- OOP costs as potential access barriers, contributing to financial toxicity and other social risk factors (adverse SDOH)
- Part D challenges (within a landscape of changes under consideration by the Biden administration)
- Regulatory issues (eg oral oncology parity laws, which vary by state)
- Patient education re: benefits and medication adherence
- Monitoring for medication adherence (more challenging than monitoring adherence with IV therapies; and also more challenging for patients on combination IV/oral therapies)
- Addressing side effects (more challenging with combination therapies)
How are practices, plans, and PBMs responding to these changes presently? How are they expected to respond within the next 18 months? What are opportunities and challenges for pharmaceutical manufacturers in this dynamic landscape? Join PRECISIONvalue’s Dominic Galante, Christy Banach, Maureen Hennessey, Janet Serluco, and Jennifer Williams for this insightful discussion.
The discussion will conclude with a live Q&A.